Development of Nerventra(R) for MS to continue
Posted: Tue May 27, 2014 1:54 am
Teva and Active Biotech to continue with the development of Nerventra(R) for MS
Teva Pharmaceutical Industries Ltd. and Active Biotech announced that the Committee for Medicinal Products for Human Use's (CHMP) confirmed its January 23, 2014 opinion to recommend against approval for the treatment of relapsing-remitting multiple sclerosis (RRMS) in the European Union (EU) at this time.
Both companies remain committed to the Nerventra(R) (laquinimod) clinical development program for multiple sclerosis (MS) and are focused on evaluating the CHMP feedback to determine potential next steps............ Read More - http://www.ms-uk.org/laquinimod
Teva Pharmaceutical Industries Ltd. and Active Biotech announced that the Committee for Medicinal Products for Human Use's (CHMP) confirmed its January 23, 2014 opinion to recommend against approval for the treatment of relapsing-remitting multiple sclerosis (RRMS) in the European Union (EU) at this time.
Both companies remain committed to the Nerventra(R) (laquinimod) clinical development program for multiple sclerosis (MS) and are focused on evaluating the CHMP feedback to determine potential next steps............ Read More - http://www.ms-uk.org/laquinimod